Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
661-680 of 998 trials

Cardiogenic Shock: Levosimendan vs. Placebo

We are studying whether early use of levosimendan can improve health outcomes in patients with cardiogenic shock compared to a placebo. The goal is to see if it reduces the need for life support and improves survival rates.

Cardiogenic Shock>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Giant Cell Arteritis and Polymyalgia Rheumatica: Hydrocortisone Study

We are investigating whether hydrocortisone can help patients with GCA and PMR who report symptoms of adrenal insufficiency after stopping glucocorticoids. This study aims to provide better treatment options for these patients.

Tertiary Adrenal Insufficiency>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Alzheimer's Agitation: Masupirdine Study

We are investigating whether masupirdine can help reduce agitation symptoms in people with Alzheimer's. The study will compare its effects to a placebo over 12 weeks.

Alzheimer's Disease3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Chronic Kidney Disease: Sevuparin Treatment Study

We are investigating how sevuparin may improve kidney function and anemia in people with chronic kidney disease. The study will assess safety and how the drug works in the body.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab with Y-90 SIRT

We are studying a combination of immunotherapy and radiation therapy for patients with intermediate stage liver cancer who cannot have surgery. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Advanced Breast Cancer: Capivasertib and Fulvestrant Study

We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Semaglutide for Obesity and Resistant Hypertension

We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.

Resistant HypertensionObesity6-12 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Influenza Vaccination: Antibody Responses Study

We are investigating how intranasal and intramuscular flu vaccines affect antibody levels in the nose. This research may help improve future vaccination methods.

Healthy Participants≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Pulmonary Hypertension: Mosliciguat Study

We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.

Pulmonary Hypertension6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Caffeine Treatment for Early Alzheimer's Disease

We are studying whether a 30-week caffeine treatment can help improve thinking and memory in people with early to moderate Alzheimer's disease. This trial compares the effects of caffeine to a placebo to see if it makes a difference.

Alzheimer's Disease6-12 monthsConfirmation phase (III)Investigational MedicinesPartially RemoteNeurology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Pulmonary Hypertension: TX000045 Treatment Study

We are testing a new medication, TX000045, for patients with pulmonary hypertension due to heart failure. The goal is to see if it improves heart function and is safe for use.

Pulmonary Hypertension3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine